董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James A. Bristol | 男 | Director | 74 | 5.18万美元 | 未持股 | 2021-06-30 |
| Bihua Chen | 女 | Director | 53 | 未披露 | 未持股 | 2021-06-30 |
| Valerie Harding Start | -- | Director | 62 | 5.18万美元 | 未持股 | 2021-06-30 |
| Michael D. Varney | 男 | Director, Chair of Research and Development and SAB member | 63 | 19.92万美元 | 未持股 | 2021-06-30 |
| Alexander W. Casdin | 男 | Director | 53 | 5.18万美元 | 未持股 | 2021-06-30 |
| Julie Hambleton | 女 | Director | 63 | 未披露 | 未持股 | 2021-06-30 |
| Pratik S. Multani | 男 | Director | 54 | 5.18万美元 | 未持股 | 2021-06-30 |
| Jonathan E. Lim | 男 | Chairman, Chief Executive Officer and Co-Founder | 49 | 196.47万美元 | 未持股 | 2021-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David M. Chacko | 男 | Chief Financial Officer | 39 | 66.28万美元 | 未持股 | 2021-06-30 |
| Ebun S. Garner | 男 | General Counsel and Corporate Secretary | 49 | 未披露 | 未持股 | 2021-06-30 |
| Wei Lin | 男 | Chief Medical Officer | 60 | 未披露 | 未持股 | 2021-06-30 |
| Jonathan E. Lim | 男 | Chairman, Chief Executive Officer and Co-Founder | 49 | 196.47万美元 | 未持股 | 2021-06-30 |
董事简历
中英对照 | 中文 | 英文- James A. Bristol
-
JamesA.Bristol博士自2007年8月起担任董事会成员，自2015年2月起担任董事长，自2007年9月至2015年2月担任联席董事长。Bristol博士在Schering-PloughCorporation、Parke-Davis和辉瑞公司从事药物发现研究和临床前开发工作32年，担任多个高级研究与开发职位。从2003年到2007年退休，Bristol博士担任辉瑞全球研发公司（Pfizer Global Research&Development）全球药物发现研究的高级副总裁，在那里他监管辉瑞公司7个地点的3000名科学家，因为他们在11个治疗领域生产了业内领先的候选药物。2009年，Bristol博士加入Frazier梦百合Ventures，担任高级顾问。他自2014年起担任Ignyta，Inc.董事，自2011年起担任Cadent Therapeutics，Inc.董事。Bristol博士是超过100个出版物，摘要和专利的作者，他在密歇根大学NIH博士后研究员和施贵宝医学研究所进行博士后研究。Bristol博士拥有the University of New Hampshire的有机化学博士学位和Bates College的化学学士学位。
James A. Bristol has served on our board of directors since June 2018. Dr. Bristol worked for more than three decades in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007 Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development. In 2009 Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor, and since 2007 Dr. Bristol has been working as a consultant with James Bristol LLC. He has served as Chairperson of Deciphera Pharmaceuticals, Inc. since 2015 and as a director since 2007 as well as a director of Ignyta, Inc. from 2014 to February 2018 and Cadent Therapeutics, Inc. from 2011 to January 2021. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan NIH Postdoctoral Fellow and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College. - JamesA.Bristol博士自2007年8月起担任董事会成员，自2015年2月起担任董事长，自2007年9月至2015年2月担任联席董事长。Bristol博士在Schering-PloughCorporation、Parke-Davis和辉瑞公司从事药物发现研究和临床前开发工作32年，担任多个高级研究与开发职位。从2003年到2007年退休，Bristol博士担任辉瑞全球研发公司（Pfizer Global Research&Development）全球药物发现研究的高级副总裁，在那里他监管辉瑞公司7个地点的3000名科学家，因为他们在11个治疗领域生产了业内领先的候选药物。2009年，Bristol博士加入Frazier梦百合Ventures，担任高级顾问。他自2014年起担任Ignyta，Inc.董事，自2011年起担任Cadent Therapeutics，Inc.董事。Bristol博士是超过100个出版物，摘要和专利的作者，他在密歇根大学NIH博士后研究员和施贵宝医学研究所进行博士后研究。Bristol博士拥有the University of New Hampshire的有机化学博士学位和Bates College的化学学士学位。
- James A. Bristol has served on our board of directors since June 2018. Dr. Bristol worked for more than three decades in drug discovery, research and preclinical development at Schering-Plough Corporation, Parke-Davis and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007 Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development. In 2009 Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor, and since 2007 Dr. Bristol has been working as a consultant with James Bristol LLC. He has served as Chairperson of Deciphera Pharmaceuticals, Inc. since 2015 and as a director since 2007 as well as a director of Ignyta, Inc. from 2014 to February 2018 and Cadent Therapeutics, Inc. from 2011 to January 2021. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan NIH Postdoctoral Fellow and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.
- Bihua Chen
-
Bihua Chen自2020年12月以来一直担任我们的董事会成员。Chen女士是Cormorant Asset Management，LP的创始人，该公司是一家投资公司，专注于创新生物技术，医疗技术和生命科学公司，并自2013年2月成立以来管理Cormorant’；s对冲基金及其私募股权基金。创立Cormorant之前，Chen从2005年到2010年担任Millennium Management LLC（一家多策略对冲基金）副顾问。此前，从2001年到2002年，陈女士是投资顾问美国运通资产管理公司（American Express Asset Management）的梦百合分析师和行业组合经理。陈女士还曾于2001年至2002年担任Asterion Life Science Fund的投资组合经理，2000年至2001年担任Bellevue Research的股票分析师和投资组合经理，1998年至2001年担任Putnam Investments的股票分析师。陈女士目前在Atia Vision，U.S.（一家私人持有的医疗创新枢纽）的董事会任职。陈女士拥有中国上海复旦大学遗传学和基因工程学士学位，康奈尔医学院生物医学科学研究生院分子生物学硕士学位和沃顿商学院工商管理硕士学位。
Bihua Chen has served as the Chairperson and Chief Executive Officer since September 2025. Ms. Chen is the founder and managing member of Cormorant. Ms. Chen was the Chief Executive Officer and Chairperson of Helix I from its inception until April 2022, when Helix I completed its business combination with MoonLake. Ms. Chen was also the Chief Executive Officer and Chairperson of Helix II from its inception until August 2025, when Helix II completed its business combination with BBOT, of which she currently serves on the board of directors. Prior to founding Cormorant in 2013, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub adviser to a large, multi strategy hedge fund based in New York. Prior to that, Ms. Chen was a healthcare analyst and sector portfolio manager for American Express Asset Management, Boston. Ms. Chen has also served as a portfolio manager for the Asterion Life Science Fund from 2001 through 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 through 2001 and an equity analyst for Putnam Investments from 1998 through 2001. Ms. Chen obtained a Master of Business Administration degree from the Wharton School of Business in 1998 and graduated with a Master of Science degree in Molecular Biology from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990. - Bihua Chen自2020年12月以来一直担任我们的董事会成员。Chen女士是Cormorant Asset Management，LP的创始人，该公司是一家投资公司，专注于创新生物技术，医疗技术和生命科学公司，并自2013年2月成立以来管理Cormorant’；s对冲基金及其私募股权基金。创立Cormorant之前，Chen从2005年到2010年担任Millennium Management LLC（一家多策略对冲基金）副顾问。此前，从2001年到2002年，陈女士是投资顾问美国运通资产管理公司（American Express Asset Management）的梦百合分析师和行业组合经理。陈女士还曾于2001年至2002年担任Asterion Life Science Fund的投资组合经理，2000年至2001年担任Bellevue Research的股票分析师和投资组合经理，1998年至2001年担任Putnam Investments的股票分析师。陈女士目前在Atia Vision，U.S.（一家私人持有的医疗创新枢纽）的董事会任职。陈女士拥有中国上海复旦大学遗传学和基因工程学士学位，康奈尔医学院生物医学科学研究生院分子生物学硕士学位和沃顿商学院工商管理硕士学位。
- Bihua Chen has served as the Chairperson and Chief Executive Officer since September 2025. Ms. Chen is the founder and managing member of Cormorant. Ms. Chen was the Chief Executive Officer and Chairperson of Helix I from its inception until April 2022, when Helix I completed its business combination with MoonLake. Ms. Chen was also the Chief Executive Officer and Chairperson of Helix II from its inception until August 2025, when Helix II completed its business combination with BBOT, of which she currently serves on the board of directors. Prior to founding Cormorant in 2013, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub adviser to a large, multi strategy hedge fund based in New York. Prior to that, Ms. Chen was a healthcare analyst and sector portfolio manager for American Express Asset Management, Boston. Ms. Chen has also served as a portfolio manager for the Asterion Life Science Fund from 2001 through 2002, an equity analyst and portfolio manager for Bellevue Research from 2000 through 2001 and an equity analyst for Putnam Investments from 1998 through 2001. Ms. Chen obtained a Master of Business Administration degree from the Wharton School of Business in 1998 and graduated with a Master of Science degree in Molecular Biology from the Graduate School of Biomedical Science at Cornell Medical College in 1994. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China, which she received in 1990.
- Valerie Harding Start
-
Valerie Harding Start自2019年6月以来一直在我们的董事会任职。自2019年2月以来，Harding-Start博士一直担任Start Pharma Consulting LLC的负责人和顾问。从2015年到2019年1月，Harding-Start博士担任Ignyta，Inc.’；化学、制造和控制CMC的高级副总裁，以及Ignyta’；S被Roche收购期间的场长。在加入Ignyta之前，Harding-Start博士担任Pfizer，Inc.全球研究与开发的药物科学产品差异化副总裁。Harding-Start博士也是SmalLify LLC（一家创新能力建设公司）的实践和思想社区合伙人。Harding-Start博士持有B.Pharm。伦敦大学药学微生物学博士，诺丁汉大学药物微生物学博士。
Valerie Harding Start has served on our board of directors since June 2019. Since February 2019 Dr. Harding-Start has been a principal and advisor at Start Pharma Consulting LLC. From 2015 to January 2019 Dr. Harding-Start served as Ignyta, Inc.’s Senior Vice President of Chemistry, Manufacturing and Controls CMC, as well as Site Head during Ignyta’s acquisition by Roche. Prior to Ignyta, Dr. Harding-Start served as Vice President of Product Differentiation, Pharmaceutical Sciences for Worldwide Research and Development at Pfizer, Inc. Dr. Harding-Start is also a member of the community of practice and thought partner for Smallify LLC, an innovation capacity-building firm. Dr. Harding-Start holds a B. Pharm. from the University of London and a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham. - Valerie Harding Start自2019年6月以来一直在我们的董事会任职。自2019年2月以来，Harding-Start博士一直担任Start Pharma Consulting LLC的负责人和顾问。从2015年到2019年1月，Harding-Start博士担任Ignyta，Inc.’；化学、制造和控制CMC的高级副总裁，以及Ignyta’；S被Roche收购期间的场长。在加入Ignyta之前，Harding-Start博士担任Pfizer，Inc.全球研究与开发的药物科学产品差异化副总裁。Harding-Start博士也是SmalLify LLC（一家创新能力建设公司）的实践和思想社区合伙人。Harding-Start博士持有B.Pharm。伦敦大学药学微生物学博士，诺丁汉大学药物微生物学博士。
- Valerie Harding Start has served on our board of directors since June 2019. Since February 2019 Dr. Harding-Start has been a principal and advisor at Start Pharma Consulting LLC. From 2015 to January 2019 Dr. Harding-Start served as Ignyta, Inc.’s Senior Vice President of Chemistry, Manufacturing and Controls CMC, as well as Site Head during Ignyta’s acquisition by Roche. Prior to Ignyta, Dr. Harding-Start served as Vice President of Product Differentiation, Pharmaceutical Sciences for Worldwide Research and Development at Pfizer, Inc. Dr. Harding-Start is also a member of the community of practice and thought partner for Smallify LLC, an innovation capacity-building firm. Dr. Harding-Start holds a B. Pharm. from the University of London and a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham.
- Michael D. Varney
-
Michael D.Varney自2020年8月起担任我们的研究与开发主席和科学顾问委员会成员，自2020年12月起担任我们的董事会成员。从2005年到2020年7月退休，Varney博士担任Genentech，Inc.的进步职务，最近担任执行副总裁兼研究和早期开发主管，以及Roche，Genentech’；S母公司的企业执行委员会成员。在加入Genentech之前，从1987年到2005年，Varney博士担任Agouron Pharmaceuticals，Inc.的研究主管，这是一家生物技术公司，后来被辉瑞公司收购。Varney博士从2015年到2018年3月担任Roche Holdings AG收购的FoundationMedicine，Inc.的董事会成员。Varney博士是哥伦比亚大学美国癌症协会博士后，拥有加州大学洛杉矶分校化学学士学位和加州理工学院合成有机化学博士学位。
Michael D. Varney has served as our Chair of Research and Development and Scientific Advisory Board member since August 2020 and on our board of directors since December 2020. From 2005 until his retirement in July 2020 Dr. Varney served in progressing roles at Genentech, Inc., most recently as Executive Vice President and Head of Research and Early Development, as well as a member of the Corporate Executive Committee of Roche, Genentech’s parent company. Prior to Genentech, from 1987 to 2005 Dr. Varney served as Head of Research at Agouron Pharmaceuticals, Inc., a biotechnology company later acquired by Pfizer, Inc. Dr. Varney served on the board of directors of Foundation Medicine, Inc. acquired by Roche Holdings AG from 2015 until March 2018. Dr. Varney was an American Cancer Society postdoctoral fellow at Columbia University, and holds a B.S. in chemistry from the University of California, Los Angeles and a Ph.D. in synthetic organic chemistry from the California Institute of Technology. - Michael D.Varney自2020年8月起担任我们的研究与开发主席和科学顾问委员会成员，自2020年12月起担任我们的董事会成员。从2005年到2020年7月退休，Varney博士担任Genentech，Inc.的进步职务，最近担任执行副总裁兼研究和早期开发主管，以及Roche，Genentech’；S母公司的企业执行委员会成员。在加入Genentech之前，从1987年到2005年，Varney博士担任Agouron Pharmaceuticals，Inc.的研究主管，这是一家生物技术公司，后来被辉瑞公司收购。Varney博士从2015年到2018年3月担任Roche Holdings AG收购的FoundationMedicine，Inc.的董事会成员。Varney博士是哥伦比亚大学美国癌症协会博士后，拥有加州大学洛杉矶分校化学学士学位和加州理工学院合成有机化学博士学位。
- Michael D. Varney has served as our Chair of Research and Development and Scientific Advisory Board member since August 2020 and on our board of directors since December 2020. From 2005 until his retirement in July 2020 Dr. Varney served in progressing roles at Genentech, Inc., most recently as Executive Vice President and Head of Research and Early Development, as well as a member of the Corporate Executive Committee of Roche, Genentech’s parent company. Prior to Genentech, from 1987 to 2005 Dr. Varney served as Head of Research at Agouron Pharmaceuticals, Inc., a biotechnology company later acquired by Pfizer, Inc. Dr. Varney served on the board of directors of Foundation Medicine, Inc. acquired by Roche Holdings AG from 2015 until March 2018. Dr. Varney was an American Cancer Society postdoctoral fellow at Columbia University, and holds a B.S. in chemistry from the University of California, Los Angeles and a Ph.D. in synthetic organic chemistry from the California Institute of Technology.
- Alexander W. Casdin
-
AlexanderW.Casdin于2009年1月29日首次被选入董事会，他是我们薪酬委员会以及提名和公司治理委员会的成员。他是Protox Therapeutics Corporation的首席财务官，自2011年10月以来一直担任该职位。任职Protox公司之前，他曾担任AmylinPharmaceuticals，Inc.公司的财务Vice President（从2009年11月到2011年9月）。任职Amylin公司之前，他曾担任Casdin Advisors公司（成立于2007年）的创始人，在那里他曾担任生命科学行业公司的战略顾问。从2005年10月到他创立Casdin Advisors，Casdin先生是梦百合投资基金Cooper Hill Partners，LLC的首席执行官兼投资组合经理，从2001年到2005年10月，他是Cooper Hill Partners的联合投资组合经理。从1999年到2001年，Casdin先生受聘于Pequot Capital Management，LLC，担任分析师，然后担任投资组合经理，在那里他监督Pequot Capital梦百合基金。在加入Pequot Capital Management之前，Casdin先生是Dreyfus Corporation的高级管理分析师，专注于梦百合行业。在非营利部门，Casdin先生是哥伦比亚商学院（Columbia Business School）社会企业项目的成员，是位于纽约大学Langone医学中心的Hassenfeld Center for Cancer&Blood Disorders的顾问委员会成员，也是Whitney Museum of American Art的艺术家理事会成员。Casdin先生在布朗大学（Brown University）获得学士学位，并在哥伦比亚商学院（Columbia Business School）获得Beta Gamma Sigma工商管理硕士学位。
Alexander W. Casdin has served on our board of directors since July 2018. Mr. Casdin has served as Chief Financial Officer of Epirium Bio Inc. since October 2020. Previously, Mr. Casdin was the founder and served as the Chief Executive Officer and portfolio manager of Reneo Capital Management LP from January 2015 to October 2020. From September 2012 through December 2014 Mr. Casdin was a private investor focused on the healthcare sector. From October 2011 through September 2012 Mr. Casdin was the Chief Financial Officer of Sophiris Bio, Inc., a Canadian public urology company. Prior to Sophiris Bio, Mr. Casdin served as the Vice President, Finance of Amylin Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Bristol-Myers Squibb in 2012 a position he held from October 2009 to October 2011. Prior to his position at Amylin Pharmaceuticals, Mr. Casdin founded and operated Casdin Advisors LLC, where he served as a strategic advisor to companies in the life sciences industry. Before founding Casdin Advisors, Mr. Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund. Mr. Casdin has also held previous positions at Pequot Capital Management and Dreyfus Corporation. Mr. Casdin has served on the board of directors for multiple life sciences companies, including Ignyta, Inc. from 2013 to 2018 and DUSA Pharmaceuticals Inc. from 2009 to 2012. Mr. Casdin holds a B.A. in political science from Brown University and an M.B.A. from Columbia Business School, where he graduated Beta Gamma Sigma. - AlexanderW.Casdin于2009年1月29日首次被选入董事会，他是我们薪酬委员会以及提名和公司治理委员会的成员。他是Protox Therapeutics Corporation的首席财务官，自2011年10月以来一直担任该职位。任职Protox公司之前，他曾担任AmylinPharmaceuticals，Inc.公司的财务Vice President（从2009年11月到2011年9月）。任职Amylin公司之前，他曾担任Casdin Advisors公司（成立于2007年）的创始人，在那里他曾担任生命科学行业公司的战略顾问。从2005年10月到他创立Casdin Advisors，Casdin先生是梦百合投资基金Cooper Hill Partners，LLC的首席执行官兼投资组合经理，从2001年到2005年10月，他是Cooper Hill Partners的联合投资组合经理。从1999年到2001年，Casdin先生受聘于Pequot Capital Management，LLC，担任分析师，然后担任投资组合经理，在那里他监督Pequot Capital梦百合基金。在加入Pequot Capital Management之前，Casdin先生是Dreyfus Corporation的高级管理分析师，专注于梦百合行业。在非营利部门，Casdin先生是哥伦比亚商学院（Columbia Business School）社会企业项目的成员，是位于纽约大学Langone医学中心的Hassenfeld Center for Cancer&Blood Disorders的顾问委员会成员，也是Whitney Museum of American Art的艺术家理事会成员。Casdin先生在布朗大学（Brown University）获得学士学位，并在哥伦比亚商学院（Columbia Business School）获得Beta Gamma Sigma工商管理硕士学位。
- Alexander W. Casdin has served on our board of directors since July 2018. Mr. Casdin has served as Chief Financial Officer of Epirium Bio Inc. since October 2020. Previously, Mr. Casdin was the founder and served as the Chief Executive Officer and portfolio manager of Reneo Capital Management LP from January 2015 to October 2020. From September 2012 through December 2014 Mr. Casdin was a private investor focused on the healthcare sector. From October 2011 through September 2012 Mr. Casdin was the Chief Financial Officer of Sophiris Bio, Inc., a Canadian public urology company. Prior to Sophiris Bio, Mr. Casdin served as the Vice President, Finance of Amylin Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Bristol-Myers Squibb in 2012 a position he held from October 2009 to October 2011. Prior to his position at Amylin Pharmaceuticals, Mr. Casdin founded and operated Casdin Advisors LLC, where he served as a strategic advisor to companies in the life sciences industry. Before founding Casdin Advisors, Mr. Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund. Mr. Casdin has also held previous positions at Pequot Capital Management and Dreyfus Corporation. Mr. Casdin has served on the board of directors for multiple life sciences companies, including Ignyta, Inc. from 2013 to 2018 and DUSA Pharmaceuticals Inc. from 2009 to 2012. Mr. Casdin holds a B.A. in political science from Brown University and an M.B.A. from Columbia Business School, where he graduated Beta Gamma Sigma.
- Julie Hambleton
-
Julie Hambleton，自2021年3月起在Erasca，Inc.董事会任职。2020年8月至2021年3月，汉布尔顿博士担任私营生物技术公司Arch Therapeutics，Inc.的临时总裁兼首席执行官。从2018年6月到2020年4月退休，汉布尔顿博士在肿瘤医药公司IDEAYA生物科学公司担任高级副总裁、首席医疗官、开发主管。2017年9月至2018年5月，2016年3月至2016年5月，汉布尔顿博士担任多家生命科学公司的独立战略顾问。2016年5月至2017年9月，她在全球生物制药公司百时美施贵宝担任副总裁兼美国医疗主管。2015年8月至2016年2月，汉布尔顿博士在生物技术公司Five Prime Therapeutics担任执行副总裁兼首席医疗官，并于2012年12月至2015年8月担任高级副总裁兼首席医疗官。从2010年4月到2012年11月，汉布尔顿博士在Clovis肿瘤药物担任临床开发副总裁。从2003年到2010年，汉布尔顿博士在基因泰克的生物肿瘤学领域担任越来越重要的职务。汉布尔顿博士在两家上市生物技术公司的董事会任职：IGM Biosciences，Inc.，自2018年8月起；SpringWorks Therapeutics，Inc.，自2020年5月起。汉布尔顿博士在加州大学旧金山分校完成了血液肿瘤学培训，随后她于1993年至2003年在该学院任职。汉布尔顿博士拥有杜克大学的护理学士学位和凯斯西储大学医学院的医学博士学位，并获得血液学和内科医学的董事会认证。
Julie Hambleton has served on Erasca, Inc. board of directors since March 2021. From August 2020 to March 2021 Dr. Hambleton served as interim President and Chief Executive Officer of Arch Therapeutics, Inc., a private biotechnology company. From June 2018 to April 2020 when she retired, Dr. Hambleton was Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, Inc., an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016 Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017 she served as Vice President, Head US Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016 Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012 Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010 Dr. Hambleton held roles of increasing responsibility in BioOncology at Genentech. Dr. Hambleton serves on the boards of two publicy-traded biotechnology companies: IGM Biosciences, Inc., since August 2018 and SpringWorks Therapeutics, Inc., since May 2020. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton holds a B.S. in nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and is board-certified in hematology and internal medicine. - Julie Hambleton，自2021年3月起在Erasca，Inc.董事会任职。2020年8月至2021年3月，汉布尔顿博士担任私营生物技术公司Arch Therapeutics，Inc.的临时总裁兼首席执行官。从2018年6月到2020年4月退休，汉布尔顿博士在肿瘤医药公司IDEAYA生物科学公司担任高级副总裁、首席医疗官、开发主管。2017年9月至2018年5月，2016年3月至2016年5月，汉布尔顿博士担任多家生命科学公司的独立战略顾问。2016年5月至2017年9月，她在全球生物制药公司百时美施贵宝担任副总裁兼美国医疗主管。2015年8月至2016年2月，汉布尔顿博士在生物技术公司Five Prime Therapeutics担任执行副总裁兼首席医疗官，并于2012年12月至2015年8月担任高级副总裁兼首席医疗官。从2010年4月到2012年11月，汉布尔顿博士在Clovis肿瘤药物担任临床开发副总裁。从2003年到2010年，汉布尔顿博士在基因泰克的生物肿瘤学领域担任越来越重要的职务。汉布尔顿博士在两家上市生物技术公司的董事会任职：IGM Biosciences，Inc.，自2018年8月起；SpringWorks Therapeutics，Inc.，自2020年5月起。汉布尔顿博士在加州大学旧金山分校完成了血液肿瘤学培训，随后她于1993年至2003年在该学院任职。汉布尔顿博士拥有杜克大学的护理学士学位和凯斯西储大学医学院的医学博士学位，并获得血液学和内科医学的董事会认证。
- Julie Hambleton has served on Erasca, Inc. board of directors since March 2021. From August 2020 to March 2021 Dr. Hambleton served as interim President and Chief Executive Officer of Arch Therapeutics, Inc., a private biotechnology company. From June 2018 to April 2020 when she retired, Dr. Hambleton was Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, Inc., an oncology medicine company. From September 2017 to May 2018 and from March 2016 to May 2016 Dr. Hambleton served as an independent strategic consultant for various life sciences companies. From May 2016 to September 2017 she served as Vice President, Head US Medical at Bristol-Myers Squibb, a global biopharmaceutical company. From August 2015 to February 2016 Dr. Hambleton served as Executive Vice President, Chief Medical Officer at Five Prime Therapeutics, a biotechnology company, and as Senior Vice President, Chief Medical Officer from December 2012 to August 2015. From April 2010 to November 2012 Dr. Hambleton served as Vice President, Clinical Development at Clovis Oncology, and from 2003 to 2010 Dr. Hambleton held roles of increasing responsibility in BioOncology at Genentech. Dr. Hambleton serves on the boards of two publicy-traded biotechnology companies: IGM Biosciences, Inc., since August 2018 and SpringWorks Therapeutics, Inc., since May 2020. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, where she then served on the faculty from 1993 to 2003. Dr. Hambleton holds a B.S. in nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine, and is board-certified in hematology and internal medicine.
- Pratik S. Multani
-
Pratik S. Multani， 理学硕士学位。自2013年5月起担任公司首席医疗官；之前从2011年5月到2013年5月担任临床开发高级副总裁；2009年4月到2011年5月担任临床开发副总裁。在此之前，他从2007年8月到2009年3月担任 Kalypsys公司（一家制药公司）临床开发副总裁，在疼痛、炎症和代谢性疾病治疗领域，提出了多种化合物的发展。从2005年到2007年他担任Kanisa制药（肿瘤科为重点的制药公司）临床研发高级副总裁和首席医疗官。1999年到2004年从Biogen-Idec公司肿瘤内科副主任的职位上升到医学研究高级总监的职位。他持有哈佛公共卫生学院流传病学学士学位；哈佛商学院硕士学位以及耶鲁大学化学和生物学士学位。他在马萨诸塞州总医院完成了内科住院医师的工作，并获得Dana Farber /合作伙伴联合计划内科肿瘤学奖学金，在此之前曾担任马萨诸塞州总医院移植部门的成员。
Pratik S. Multani has served on our board of directors since July 2018. Dr. Multani has served as Chief Medical Officer of ORIC Pharmaceuticals, Inc., a public oncology therapeutic company, since September 2018. From 2015 to February 2018 Dr. Multani served as the Chief Medical Officer of Ignyta, Inc. From 2009 to 2015 Dr. Multani was Chief Medical Officer at Fate Therapeutics, Inc., a biopharmaceutical company. Prior to that, Dr. Multani was Vice President of Clinical Development at Kalypsys, Inc. and Senior Vice President of Clinical Development and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. Dr. Multani also held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed his internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana-Farber/Partners combined program. Dr. Multani has served on the board of directors of Chimerix, Inc., a public biopharmaceutical company, since February 2020. Dr. Multani holds an M.D. from Harvard Medical School, an M.S. in epidemiology from the Harvard School of Public Health and a B.S. in chemistry and biology from Yale University. - Pratik S. Multani， 理学硕士学位。自2013年5月起担任公司首席医疗官；之前从2011年5月到2013年5月担任临床开发高级副总裁；2009年4月到2011年5月担任临床开发副总裁。在此之前，他从2007年8月到2009年3月担任 Kalypsys公司（一家制药公司）临床开发副总裁，在疼痛、炎症和代谢性疾病治疗领域，提出了多种化合物的发展。从2005年到2007年他担任Kanisa制药（肿瘤科为重点的制药公司）临床研发高级副总裁和首席医疗官。1999年到2004年从Biogen-Idec公司肿瘤内科副主任的职位上升到医学研究高级总监的职位。他持有哈佛公共卫生学院流传病学学士学位；哈佛商学院硕士学位以及耶鲁大学化学和生物学士学位。他在马萨诸塞州总医院完成了内科住院医师的工作，并获得Dana Farber /合作伙伴联合计划内科肿瘤学奖学金，在此之前曾担任马萨诸塞州总医院移植部门的成员。
- Pratik S. Multani has served on our board of directors since July 2018. Dr. Multani has served as Chief Medical Officer of ORIC Pharmaceuticals, Inc., a public oncology therapeutic company, since September 2018. From 2015 to February 2018 Dr. Multani served as the Chief Medical Officer of Ignyta, Inc. From 2009 to 2015 Dr. Multani was Chief Medical Officer at Fate Therapeutics, Inc., a biopharmaceutical company. Prior to that, Dr. Multani was Vice President of Clinical Development at Kalypsys, Inc. and Senior Vice President of Clinical Development and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. Dr. Multani also held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed his internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana-Farber/Partners combined program. Dr. Multani has served on the board of directors of Chimerix, Inc., a public biopharmaceutical company, since February 2020. Dr. Multani holds an M.D. from Harvard Medical School, an M.S. in epidemiology from the Harvard School of Public Health and a B.S. in chemistry and biology from Yale University.
- Jonathan E. Lim
-
Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc. - Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
- Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.
高管简历
中英对照 | 中文 | 英文- David M. Chacko
David M.Chacko自2020年12月起担任我们的首席财务官，并于2019年8月加入Erasca担任我们的首席商务官。在加入Erasca之前，他曾担任Versant Ventures（一家医疗保健风险投资公司）的负责人（从2017年9月到2019年8月），在那里他领导多个治疗领域的投资机会，并密切参与推进Versant投资组合公司的运营，通过公司组建和筹资，公司和业务发展，临床和监管活动。Chacko博士从专注于眼科护理产品的跨国公司爱尔康（Alcon）加入Versant，在那里他从2014年到2017年9月担任参谋长到首席执行官。在加入爱尔康之前，2011年至2014年，Chacko博士是麦肯锡公司（McKinsey&Company）的管理顾问。Chacko博士此前曾在SR One、Amgen和摩根士丹利担任职务。Chacko博士拥有宾夕法尼亚大学的硕士学位，沃顿商学院的工商管理硕士学位，哲学硕士学位。他毕业于牛津大学，在那里他是马歇尔学者，在南加州大学获得生物学和商学学士学位，在那里他是大学的毕业证书。
David M. Chacko has served as our Chief Financial Officer since December 2020 and joined Erasca in August 2019 as our Chief Business Officer. Prior to Erasca, Dr. Chacko was a principal at Versant Ventures, a healthcare venture capital firm, from September 2017 to August 2019 where he led investment opportunities across multiple therapeutic areas and was intimately involved in advancing several Versant portfolio companies operationally through company formation, fundraising, corporate and business development, and clinical and regulatory activities. Dr. Chacko joined Versant from Alcon, a multinational company specializing in eye care products, where he served as Chief of Staff to the Chief Executive Officer from 2014 to September 2017. Prior to Alcon, Dr. Chacko was a management consultant at McKinsey & Company from 2011 to 2014. Dr. Chacko previously held positions at SR One, Amgen, and Morgan Stanley. Dr. Chacko holds an M.D. from the University of Pennsylvania, an M.B.A. from the Wharton School of Business, an M. Phil. from Oxford University, where he was a Marshall Scholar, and B.A. and B.S. degrees in biology and business from the University of Southern California, where he was the university valedictorian.- David M.Chacko自2020年12月起担任我们的首席财务官，并于2019年8月加入Erasca担任我们的首席商务官。在加入Erasca之前，他曾担任Versant Ventures（一家医疗保健风险投资公司）的负责人（从2017年9月到2019年8月），在那里他领导多个治疗领域的投资机会，并密切参与推进Versant投资组合公司的运营，通过公司组建和筹资，公司和业务发展，临床和监管活动。Chacko博士从专注于眼科护理产品的跨国公司爱尔康（Alcon）加入Versant，在那里他从2014年到2017年9月担任参谋长到首席执行官。在加入爱尔康之前，2011年至2014年，Chacko博士是麦肯锡公司（McKinsey&Company）的管理顾问。Chacko博士此前曾在SR One、Amgen和摩根士丹利担任职务。Chacko博士拥有宾夕法尼亚大学的硕士学位，沃顿商学院的工商管理硕士学位，哲学硕士学位。他毕业于牛津大学，在那里他是马歇尔学者，在南加州大学获得生物学和商学学士学位，在那里他是大学的毕业证书。
- David M. Chacko has served as our Chief Financial Officer since December 2020 and joined Erasca in August 2019 as our Chief Business Officer. Prior to Erasca, Dr. Chacko was a principal at Versant Ventures, a healthcare venture capital firm, from September 2017 to August 2019 where he led investment opportunities across multiple therapeutic areas and was intimately involved in advancing several Versant portfolio companies operationally through company formation, fundraising, corporate and business development, and clinical and regulatory activities. Dr. Chacko joined Versant from Alcon, a multinational company specializing in eye care products, where he served as Chief of Staff to the Chief Executive Officer from 2014 to September 2017. Prior to Alcon, Dr. Chacko was a management consultant at McKinsey & Company from 2011 to 2014. Dr. Chacko previously held positions at SR One, Amgen, and Morgan Stanley. Dr. Chacko holds an M.D. from the University of Pennsylvania, an M.B.A. from the Wharton School of Business, an M. Phil. from Oxford University, where he was a Marshall Scholar, and B.A. and B.S. degrees in biology and business from the University of Southern California, where he was the university valedictorian.
- Ebun S. Garner
Ebun S.Garner自2021年4月起担任我们的总法律顾问兼公司秘书。在加入我们之前，Garner先生从2020年8月到2021年4月担任上市生物制药公司Acadia Pharmaceuticals，Inc.的助理总法律顾问。在Acadia之前，Garner先生曾担任Imbria Pharmaceuticals，Inc.（一家私人治疗公司）的首席法务官兼公司秘书，在那里他从2019年4月到2020年7月监督所有法律和知识产权事务。从2017年3月到2019年4月，他担任NeurocrineBiosciences，Inc.（上市生物制药公司）的副总法律顾问，在那里他是所有非商业法律事务和上市公司报告的主要法律支持。在此之前，他曾担任Alphatec Spine，Inc.（一家上市医疗设备公司）的高级副总裁、总法律顾问和公司秘书（从2005年到2017年2月）。从2000年到2005年，Garner先生是Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，P.C.纽约办事处的公司助理。他获得宾夕法尼亚大学经济学学士学位和纽约大学法学院法学博士学位。
Ebun S. Garner has served as our General Counsel and Corporate Secretary since April 2021. Prior to joining us, Mr. Garner served as Assistant General Counsel of Acadia Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from August 2020 until April 2021. Prior to Acadia, Mr. Garner served as the Chief Legal Officer and Corporate Secretary of Imbria Pharmaceuticals, Inc., a private therapeutics company, where he oversaw all legal and intellectual property matters from April 2019 to July 2020. From March 2017 to April 2019 Mr. Garner served as Associate General Counsel at Neurocrine Biosciences, Inc., a publicly-traded biopharmaceutical company, where he was the primary legal support for all non-commercial legal matters and public company reporting. Prior to that, Mr. Garner served as the Senior Vice President, General Counsel and Corporate Secretary of Alphatec Spine, Inc., a publicly-traded medical device company, where he worked from 2005 until February 2017. Mr. Garner was a corporate associate in the New York office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. from 2000 to 2005. He received a B.A. in Economics from the University of Pennsylvania and a J.D. from New York University School of Law.- Ebun S.Garner自2021年4月起担任我们的总法律顾问兼公司秘书。在加入我们之前，Garner先生从2020年8月到2021年4月担任上市生物制药公司Acadia Pharmaceuticals，Inc.的助理总法律顾问。在Acadia之前，Garner先生曾担任Imbria Pharmaceuticals，Inc.（一家私人治疗公司）的首席法务官兼公司秘书，在那里他从2019年4月到2020年7月监督所有法律和知识产权事务。从2017年3月到2019年4月，他担任NeurocrineBiosciences，Inc.（上市生物制药公司）的副总法律顾问，在那里他是所有非商业法律事务和上市公司报告的主要法律支持。在此之前，他曾担任Alphatec Spine，Inc.（一家上市医疗设备公司）的高级副总裁、总法律顾问和公司秘书（从2005年到2017年2月）。从2000年到2005年，Garner先生是Mintz，Levin，Cohn，Ferris，Glovsky和Popeo，P.C.纽约办事处的公司助理。他获得宾夕法尼亚大学经济学学士学位和纽约大学法学院法学博士学位。
- Ebun S. Garner has served as our General Counsel and Corporate Secretary since April 2021. Prior to joining us, Mr. Garner served as Assistant General Counsel of Acadia Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from August 2020 until April 2021. Prior to Acadia, Mr. Garner served as the Chief Legal Officer and Corporate Secretary of Imbria Pharmaceuticals, Inc., a private therapeutics company, where he oversaw all legal and intellectual property matters from April 2019 to July 2020. From March 2017 to April 2019 Mr. Garner served as Associate General Counsel at Neurocrine Biosciences, Inc., a publicly-traded biopharmaceutical company, where he was the primary legal support for all non-commercial legal matters and public company reporting. Prior to that, Mr. Garner served as the Senior Vice President, General Counsel and Corporate Secretary of Alphatec Spine, Inc., a publicly-traded medical device company, where he worked from 2005 until February 2017. Mr. Garner was a corporate associate in the New York office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. from 2000 to 2005. He received a B.A. in Economics from the University of Pennsylvania and a J.D. from New York University School of Law.
- Wei Lin
韦琳自2021年1月起担任我们的首席医疗官。Lin博士于2018年10月至2021年1月从Nektar Therapeutics加入Erasca，在那里他曾担任高级副总裁兼开发主管，以及执行委员会成员。在Nektar之前，从2011年10月开始，Wei在Roche及其子公司Genentech担任越来越多的职务，最近担任肺癌和头颈癌的癌症免疫疗法的全球开发负责人。林博士也是罗氏中国肿瘤产品开发的网站负责人。从2006年到2009年，林博士在MD Anderson癌症中心任职，在那里他完成了他的医学肿瘤研究金。林博士在麻省总医院完成了内科住院治疗，拥有哈佛医学院的医学博士学位和哈弗福德学院的物理学学士学位。
Wei Lin,has served as a member of 2seventy Bio, Inc. Board of Directors since March 8, 2023. From January 2021 until April 2023, he served as the Chief Medical Officer at Erasca, Inc. where he led development strategy and execution of the company's precision oncology programs. Prior to joining Erasca, from October 2018 to January 2021, he served as Head of Development at Nektar Therapeutics where he oversaw the development of the company's immuno-oncology and immunology pipeline. Before Nektar, from October 2011, Dr. Lin was at Genentech, where he served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer. Dr. Lin also served as a faculty member at the M.D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and Neck Medical Oncology. He received a B.A. from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals, including New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology.- 韦琳自2021年1月起担任我们的首席医疗官。Lin博士于2018年10月至2021年1月从Nektar Therapeutics加入Erasca，在那里他曾担任高级副总裁兼开发主管，以及执行委员会成员。在Nektar之前，从2011年10月开始，Wei在Roche及其子公司Genentech担任越来越多的职务，最近担任肺癌和头颈癌的癌症免疫疗法的全球开发负责人。林博士也是罗氏中国肿瘤产品开发的网站负责人。从2006年到2009年，林博士在MD Anderson癌症中心任职，在那里他完成了他的医学肿瘤研究金。林博士在麻省总医院完成了内科住院治疗，拥有哈佛医学院的医学博士学位和哈弗福德学院的物理学学士学位。
- Wei Lin,has served as a member of 2seventy Bio, Inc. Board of Directors since March 8, 2023. From January 2021 until April 2023, he served as the Chief Medical Officer at Erasca, Inc. where he led development strategy and execution of the company's precision oncology programs. Prior to joining Erasca, from October 2018 to January 2021, he served as Head of Development at Nektar Therapeutics where he oversaw the development of the company's immuno-oncology and immunology pipeline. Before Nektar, from October 2011, Dr. Lin was at Genentech, where he served as the Global Development Leader for cancer immunotherapy in lung and head and neck cancer. Dr. Lin also served as a faculty member at the M.D. Anderson Cancer Center in Houston in the Department of Thoracic/Head and Neck Medical Oncology. He received a B.A. from Haverford College and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital in Boston and a fellowship in medical oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Lin has extensive clinical research experience and has been published in more than 15 peer-reviewed journals, including New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology.
- Jonathan E. Lim
Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.- Jonathan E. Lim，医学博士，Ignyta Operating的联合创始人，2011年8月成立起任主席、总裁、CEO。在2013年10月31日Ignyta Operating被Ignyta收购完成，成为其全资子公司之后，继续担任此职。加入Ignyta Operating前，他最近一职是Eclipse Therapeutics, Inc.主席和CEO，该公司是一家私营生物科技公司，开发针对癌症干细胞的单克隆抗体治疗。2011年3月，该公司由他联合创立，是 Biogen Idec的衍生公司。2012年9月出售给Bionomics Ltd.，该公司是一家澳大利亚上市生物科技公司，研究开发针对肿瘤和中枢神经系统障碍的治疗药物。他目前就任Bionomics Ltd.董事会成员。成立Eclipse Therapeutics前，2003年5月至2010年12月，他任上市生物科技公司Halozyme Therapeutics, Inc.的总裁、CEO、董事。此前，他担任过Harvard Medical School医学博士后国家研究所McKinsey & Company管理顾问，以及New York Hospital-Cornell两年外科主治医生。他拥有Stanford学士和硕士学位，McGill University医学博士学位，以及Harvard University公共卫生硕士学位。
- Jonathan E. Lim,co-founded Boundless and has served as Boundless Bio, Inc. Chairman since December 2018. Dr. Lim also co-founded Erasca, Inc., a publicly traded precision oncology company, in July 2018, joined as Executive Chairman in October 2018, and has served as Chairman and Chief Executive Officer since March 2019. Dr. Lim has also served as a Venture Partner at ARCH Venture Partners since December 2018 and as Managing Partner at City Hill, LLC since founding it in 2010. Prior to co-founding each of Boundless and Erasca in 2018, Dr. Lim co-founded and served as Chairman of Ignyta, Inc., a publicly traded precision oncology company, and led it from 2012 as Chairman, Chief Executive Officer, and President through its acquisition by Roche in February 2018 and subsequent integration into Roche and Genentech in July 2018. During his tenure at Ignyta, Dr. Lim co-founded Bonti, Inc., a privately held pain management and anesthetics company, and served as its Chairman from February 2016 until its acquisition by Allergan plc in October 2018. Prior to joining Ignyta, Dr. Lim served as Chairman and Chief Executive Officer of Eclipse Therapeutics, Inc., a privately held oncology company targeting cancer stem cells that he co-founded in March 2011 as a spinout from Biogen Idec and that was sold to Bionomics Ltd. in 2012. Prior to Eclipse, Dr. Lim served as the President, Chief Executive Officer, and a Director (including as Chairman from 2004 to 2005) of Halozyme Therapeutics, Inc., a publicly traded biotechnology company, from May 2003 to December 2010. Prior to Halozyme, Dr. Lim's experience included management consulting at McKinsey & Company, a National Institutes of Health Postdoctoral Fellowship at Harvard Medical School and the Dana-Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center. Dr. Lim has also served as a member of the board of directors of Maze Therapeutics, Inc., a private company advancing precision medicines for both rare and common diseases, since October 2019. Dr. Lim has been a member of the Board of Overseers at Scripps Research since October 2018, a member of the Board of Visitors of the Moores Cancer Center at the University of California, San Diego since 2015, and a member of the Stanford Interdisciplinary Biosciences Council since 2014. Dr. Lim has B.S. and M.S. degrees from Stanford University, an M.D. from McGill University, and an M.P.H. from Harvard University. Dr. Lim's intimate knowledge of Boundless Bio, Inc. business as a co-founder and his extensive experience as an executive officer and director of multiple public and private biotechnology companies contributed to Boundless Bio, Inc. board of directors' conclusion that he should serve as a director of Boundless Bio, Inc.